A5049331116- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- BRCA gene mutations in cancer
- Breast Lesions and Carcinomas
- Cancer Genomics and Diagnostics
- Global Cancer Incidence and Screening
- Estrogen and related hormone effects
- Drug Transport and Resistance Mechanisms
- Cancer Risks and Factors
- Cancer therapeutics and mechanisms
- Economic and Financial Impacts of Cancer
- Lung Cancer Treatments and Mutations
- PARP inhibition in cancer therapy
- Cancer survivorship and care
- Breast Implant and Reconstruction
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Monoclonal and Polyclonal Antibodies Research
- Colorectal Cancer Treatments and Studies
- Cancer Diagnosis and Treatment
- DNA Repair Mechanisms
- Cancer-related Molecular Pathways
- Bioinformatics and Genomic Networks
Fox Chase Cancer Center
2015-2024
Amgen (United States)
2023
Temple University Health System
2015-2023
Dana-Farber Cancer Institute
2003-2022
University of Colorado Denver
2015-2022
University of Colorado Cancer Center
2015-2022
Mount Sinai Health System
2022
Northwestern University
2004-2022
Temple University
2022
O'Neal Comprehensive Cancer Center
2022
Ductal carcinoma in situ (DCIS) of the breast represents a heterogeneous group neoplastic lesions ducts. The goal for management DCIS is to prevent development invasive cancer. This manuscript focuses on NCCN Guidelines Panel recommendations workup, primary treatment, risk reduction strategies, and surveillance specific DCIS.
Several new systemic therapy options have become available for patients with metastatic breast cancer, which led to improvements in survival. In addition patient and clinical factors, the treatment selection primarily depends on tumor biology (hormone-receptor status HER2-status). The NCCN Guidelines specific workup of recurrent/stage IV cancer are discussed this article.
Journal Article Expression of Multidrug Resistance Gene in Human Cancers Get access Lori J. Goldstein, Goldstein 1(Laboratory Molecular Biology, Division Cancer Biology and Diagnosis) Search for other works by this author on: Oxford Academic PubMed Google Scholar Hanan Galski, Galski Antonio Fojo, Fojo Mark Willingham, Willingham Shinn-Lian Lai, Lai 6(NCI-Navy Medical Oncology Branch, Treatment) Adi Gazdar, Gazdar Robert Pirker, Pirker 2Second ClinicGarnisongasse 13, A-1090 Vienna, Austria...
This study was designed to determine whether increasing the dose of doxorubicin in or adding paclitaxel a standard adjuvant chemotherapy regimen for breast cancer patients would prolong time recurrence and survival.After surgical treatment, 3,121 women with operable involved lymph nodes were randomly assigned receive combination cyclophosphamide (C), 600 mg/m(2), one three doses (A), 60, 75, 90 four cycles followed by either no further therapy at 175 mg/m(2). Tamoxifen given 94% hormone...
Recent studies suggest that tumor-infiltrating lymphocytes (TILs) are associated with disease-free (DFS) and overall survival (OS) in operable triple-negative breast cancer (TNBC). We seek to validate the prognostic impact of TILs primary TNBCs two adjuvant phase III trials conducted by Eastern Cooperative Oncology Group (ECOG).Full-face hematoxylin eosin–stained sections 506 tumors from ECOG E2197 E1199 were evaluated for density intraepithelial (iTILs) stromal compartments (sTILs). Patient...
The therapeutic options for patients with noninvasive or invasive breast cancer are complex and varied. These NCCN Clinical Practice Guidelines Breast Cancer include recommendations clinical management of carcinoma in situ, cancer, Paget disease, phyllodes tumor, inflammatory during pregnancy. content featured this issue focuses on the overall ductal situ workup locoregional early stage cancer. For full version Cancer, visit NCCN.org .
made in the treatment of early stage breast cancer.In patients with hormonesensitive tumors, tamoxifen reduces risk recurrence and death by more than 30%. 1 Moreover, aromatase inhibitors place or sequentially further postmenopausal women estrogenreceptor (ER)-positive tumors. [2]][4] In absence treatment, ER status is a weak prognostic factor, but it strong predictive factor sense that identifies who may benefit from endocrine therapy.With appropriate therapy, ER-positive disease have...
The status of human epidermal growth factor receptor type 2 (HER2) in breast-cancer cells predicts clinical outcomes women who receive adjuvant anthracycline-based chemotherapy. We hypothesized that HER2 positivity a benefit from doxorubicin doses above standard levels, the addition paclitaxel after chemotherapy with plus cyclophosphamide, or both.We randomly selected 1500 3121 node-positive breast cancer had been assigned to (60, 75, 90 mg per square meter body-surface area)...
Ovarian failure is a common toxic effect of chemotherapy. Studies the use gonadotropin-releasing hormone (GnRH) agonists to protect ovarian function have shown mixed results and lack data on pregnancy outcomes.
We conducted a randomized trial in which we compared high-dose chemotherapy plus hematopoietic stem-cell rescue with prolonged course of monthly conventional-dose women metastatic breast cancer.
These NCCN Guidelines Insights highlight the important updates/changes to surgical axillary staging, radiation therapy, and systemic therapy recommendations for hormone receptor-positive disease in 1.2017 version of Breast Cancer. This report summarizes these updates discusses rationale behind them. Updates on new drug approvals, not available at press time, can be found most recent guidelines NCCN.org.
The purpose of this study was to evaluate posttraumatic growth among breast cancer patients and their significant others over a 1(1/2)-year time span after diagnosis examine cognitive emotional processes in growth.One hundred sixty-two women with partners completed surveys assessing growth, processing, marital satisfaction at 3 points spaced 9 months apart.Posttraumatic increased for both during period. Patient predicted by younger age, contemplating reasons cancer, more expression 1....
Adjuvant! is a standardized validated decision aid that projects outcomes in operable breast cancer based on classical clinicopathologic features and therapy. Genomic classifiers offer the potential to more accurately identify individuals who benefit from chemotherapy than features.A sample of 465 patients with hormone receptor (HR) -positive zero three positive axillary nodes did (n = 99) or not have recurrence after chemohormonal therapy had tumor tissue evaluated using 21-gene assay....
The recurrence score based on the 21-gene breast-cancer assay has been clinically useful in predicting a chemotherapy benefit hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary lymph-node-negative breast cancer. In women with positive lymph-node disease, role of respect to adjuvant is unclear.In prospective trial, we randomly assigned HER2-negative cancer, one three lymph nodes, and 25 or lower (scores range from 0 100, higher scores indicating...
Breast cancer is the most common malignancy in women United States and second only to lung as a cause of death. The overall management breast includes treatment local disease with surgery, radiation therapy, or both, systemic cytotoxic chemotherapy, endocrine biologic combinations these. This article outlines NCCN Guidelines specific that locoregional (restricted one region body), discusses clinical stage I, II, IIIA (T3N1M0) tumors. For on adjuvant therapy after II for other stages cancer,...
The NCCN Guidelines for Breast Cancer include up-to-date guidelines clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, phyllodes tumor, inflammatory male and cancer during pregnancy. These are developed by a multidisciplinary panel representatives from Member Institutions cancer–focused expertise the fields medical oncology, surgical radiation pathology, reconstructive surgery, patient advocacy. Insights focus on most recent updates to...
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer address all aspects of management breast cancer. treatment landscape metastatic cancer is evolving constantly. therapeutic strategy takes into consideration tumor biology, biomarkers, and other clinical factors. Due to the growing number options, if one option fails, there usually another line therapy available, providing meaningful improvements survival. This Insights report focuses on recent updates...
This study was designed to assess efficacy, safety, and predictors of response iniparib in combination with gemcitabine carboplatin early-stage triple-negative BRCA1/2 mutation-associated breast cancer.This single-arm phase II enrolled patients stage I IIIA (T ≥ 1 cm) estrogen receptor-negative (≤ 5%), progesterone human epidermal growth factor receptor 2-negative or cancer. Neoadjuvant (1,000 mg/m(2) intravenously [IV] on days 8), (area under curve 2 IV (5.6 mg/kg 1, 4, 8, 11) were...
Abstract Purpose: Chemokine receptor 1 (CXCR1) is recognized as an actionable selectively expressed by breast cancer stem cells (BCSCs). Reparixin investigational allosteric inhibitor of chemokine receptors and 2 (CXCR1/2), demonstrates activity against BCSCs in human xenografts. This phase Ib clinical trial examined dose, safety, pharmacokinetics paclitaxel plus reparixin therapy, explored effects on patients with metastatic (MBC) (trial registration ID: NCT02001974). Experimental Design:...
These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy women with hormone receptor–positive, HER2-negative early-stage invasive breast cancer. This report summarizes these updates and discusses rationale behind them.
Purpose The mammalian target of rapamycin inhibitor everolimus targets aberrant signaling through the PI3K/AKT/mammalian pathway, a mechanism resistance to anti-estrogen therapy in estrogen receptor (ER)-positive breast cancer. We hypothesized that plus selective ER downregulator fulvestrant would be more efficacious than alone ER-positive metastatic cancer resistant aromatase (AI) therapy. Patients and Methods This randomized, double-blind, placebo-controlled, phase II study included 131...
Distant metastases are present in 6% or more of patients with newly diagnosed breast cancer. In this context, locoregional therapy for the intact primary tumor has been hypothesized to improve overall survival (OS), but clinical trials have reported conflicting results.